Perflutren News
Perflutren currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Perflutren with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: This medicinal product is for diagnostic use only. Optison is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide...
- Evidence level: L5
- Predicted indications (20):
- acute intermittent porphyria (97.5%)
- nephrogenic syndrome of inappropriate antidiuresis (96.6%)
- multidrug-resistant tuberculosis (96.5%)
- myocardial ischemia (96.3%)
- acute neonatal citrullinemia type I (96.0%)
- adult-onset citrullinemia type I (96.0%)
- coronary artery disease (95.7%)
- anomalous left coronary artery from the pulmonary artery (95.5%)
- tuberculoma (95.3%)
- tuberculous ascites (95.3%)
- tuberculosis, avian (95.3%)
- inactive tuberculosis (95.3%)
- tuberculosis, bovine (95.2%)
- chronic tic disorder (94.1%)
- urea cycle disorder (94.0%)
- extrapyramidal and movement disease (94.0%)
- benign shuddering attacks (94.0%)
- porphyria (94.0%)
- psychogenic movement disorders (93.8%)
- benign paroxysmal tonic upgaze of childhood with ataxia (93.8%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.